News | May 13, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
The collaboration between CORONA and Ferring will cater to patients across India
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Subscribe To Our Newsletter & Stay Updated
